We report an original application of competitive reverse transcription-polymerase chain reaction (RT-PCR) for the quantification of MDR1 mRNA in clinical specimens by simultaneous reverse transcription and PCR amplification of cellular RNA with decreasing amounts of an internal standard. The competitor RNA shares the same MDR1 primer sequences as the cellular mRNA, but yields a different-sized PCR product. This allows resolution of the amplified cDNA fragments after agarose gel electrophoresis and ethidium bromide staining. The concentration of MDR1 mRNA is derived from the ratio between the intensities of the bands corresponding to the amplified products. We have used this assay to measure MDR1 expression in breast carcinomas and assessed the precision, sensitivity, and accuracy of the method. Competitive RT-PCR is a simple, highly specific, nonradioactive procedure for the quantification of MDR1 mRNA and is particularly suitable for use in the clinical laboratory. It requires serial dilutions of the coreverse-transcribed cRNA and sample mRNA, and uses 32P end-labeled primers for the PCR. The PCR assay described herein quantitatively measures MDR1 mRNA with a synthetic "mimic" MDR1 cRNA added in serial molar dilutions to equal amounts of total RNA extracted from biological specimens.
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RNA Preparation
Total RNA from cell lines was extracted by using the guanidiium isothiocyanate procedure (30) . Total cellular RNA from tumors was isolated by the guanidinium cesium chloride method (31).
Construct of a Mimic MDR1 cRNA
The following oligonucleotides (sense, +; antisense,
were used as primers for cDNA synthesis and PCR amplification of two specific MDR1 fragments from total RNA extracted from a colon carcinoma cell line (SW 613-S). The numbers used in the designation of the primers correspond to the 5'-end nucleotide of MDR1-specific sequence (underlined), taking + 1 for the A of the initiation codon of human MDR1 cDNA (5). The recognition sequence of Sail, Hindlil, or BarnHI restriction enzyme has been added at the 5' end.
Two fragments, AE and BF, were amplified from MDR1 cDNA: The 244-bp AE fragment was amplified from A Sal 811 (-) and E Barn 586 (+) oligoculeotides, and the 202-bp BF fragment was amplified from B Hind 320 (+) and F Bam 506 (-) oligonucleotides, as shown in Fig. 1 
Image analysis.
We measured the intensity of the two bands corresponding to cellular (target) and competitor (mimic) amplification products with The Imager system from Appligene, consisting of a charge-coupled device (CCD) video camera connected to a Macintosh computer.
Image processing and analysis were performed with the NIH Image 1.43 program.
Fluorescence was recorded and the areas of the peaks were measured.
The ratio of the intensities of the two bands, with a correction factor of 0.74 accounting for the difference in size of mimic/target, provided the basis of quantification.
Results

Exponential PCR Amplification of MDR1 mRNA
To determine the exponential range of PCR amplification for MDR1 mRNA and synthetic mimic RNA, we coreverse-transcribed 1 g of total cellular RNA isolated from the human colon carcinoma cell line SW 613-S and 24.4 amol of mimic RNA into the first-strand cDNAs.
The cDNA products were then amplified for various numbers of cycles of PCR. PCR products were size-fractionated through a 2% agarose gel, stained with ethidium bromide, and quantified. Figure 2 shows the results obtained from the exponential range experiment.
Both the synthetic and the cellular MDR1 cDNAs were amplified in an exponential fashion from 26 to 35 cycles. The relative amounts of the two amplified products stayed identical all along the PCR amplification, even after 35 cycles, when the plateau phase was reached.
Quantification of MDR1 mRNA in Human Cancer Cell Lines and in Normal Human Liver
MDR1-specific cDNA sequences synthesized from oligonucleotide C were amplified with a pair of amplimers (D,C) derived from exons 6 and 7 of the MDR1 gene, respectively (32), to prevent amplification of DNA sequences that may be present in RNA preparations. The MDR1-specific amplimers were selected so that they would not amplify the closely related MDR2 cDNA sequence. We screen biological samples by using 30 cycles of PCR, i.e., during the exponential phase of amplification.
We probed a constant amount of cellular RNA (1 g) with decreasing amounts of synthetic MDR1 cRNA (from 610 to 0.19 amol). Two examples of gel resolution are shown in Fig. 3 . The 0.19 amol mimic-generated band was visible only when the MDR1 mRNA concentration of the target cellular RNA was inferior to that value. The data were quantified by computer imaging of the gel as described in Materials and Methods.
The areas of the peaks were measured and the targetlmimic ratios were plotted on a logarithmic scale against the mimic amounts in each reaction mixture of PCR amplification. The amount of MDR1 mRNA in the sample was then calculated by extrapolating from the intersection of the curve, where the amounts of target and competitor are equal (ratio = 1). When necessary, after a first assay in the conditions described above, intermediary mimic dilutions were added within the fivefold serial dilutions. Fig. 4 gives the curves obtained with total RNA extracted from SW 613-S cells (panel A) and from the HL1 ( Table 1 ).
The amount of target RNA can be determined by noting how much mimic is required to produce equal molar quantities of PCR products. After 30 cycles of amplification, one-fifth of the products were resolved on a 2% agarose gel and stained with ethidium bromide. 
Assay Evaluation
Linearity.
In the experiments reported above, a constant amount of cellular RNA (1 g) was probed with decreasing amounts of synthetic MDR1 cRNA in the presence of specific primers designed for RT-PCR. The following assay was performed to evaluate the linearity between the amount of initial cellular MDR1 RNA and the PCR product obtained after 30 cycles of amplification. We probed a constant amount of MDR1 competitor (24.4 amol) with increasing amounts of total RNA from colon carcinoma cell line SW 613-S (from 0.7 to 2.5 g, i.e., 24.5-87.5 amol of MDR1 mRNA) and processed this as in the previous experiments. We observed a linear response (r = 0.98, Fig. 5 ). The wide range of linearity indicates that the assay can be used reliably with samples having a wide range of MDR1 mRNA concentrations.
Accuracy.
To test the accuracy of this method, we mixed decreasing amounts of normal human liver RNA HL1 (9-1 p.g, i.e., 18-2 amol of MDR1 mRNA) with increasing amounts of human colon carcinoma cell line SW 613-S-extracted RNA (1-9 p.g, i.e., 35-315 amol of MDR1 RNA) to obtain a final concentration of 10 g of RNA in 10 p1 of water.
Competitive RT-PCR was applied to 1:10 dilutions of the different mixes. The experimental values plotted against the expected ones (Fig. 6) showed the ability of competitive RT-PCR to Increasing amounts of total RNA from colon carcinoma cell line SW 613-S (0.7, 1, 1.3, 1.9, and 2.5 g, i.e., 24.5, 45.5, 46.1,66.5, and 87.5 amol) were probed with a constant amount of mimic RNA (24.4 amol). These samples were amplified in a 30-cycle PCR and the amplification products were resolved on a 2% agarose gel. After ethidlum bromide staining, target/mimic ratios were measured and plotted on a logarithmic scale vs the target MDR1 mRNA amounts.
Units as in Table 1 .
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